Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Gains from Sales and Divestitures (2018)

Historic Gains from Sales and Divestitures for Spyre Therapeutics (SYRE) over the last 2 years, with Q4 2018 value amounting to $26444.0.

  • Spyre Therapeutics' Gains from Sales and Divestitures changed N/A to $26444.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $26444.0, marking a year-over-year change of. This contributed to the annual value of $26444.0 for FY2018, which is N/A changed from last year.
  • As of Q4 2018, Spyre Therapeutics' Gains from Sales and Divestitures stood at $26444.0.
  • In the past 5 years, Spyre Therapeutics' Gains from Sales and Divestitures ranged from a high of $32588.0 in Q4 2015 and a low of $26444.0 during Q4 2018